A case of sarcoidosis‐like reaction associated with immune checkpoint inhibitors in metastatic renal cell carcinoma

A case of sarcoidosis‐like reaction associated with immune checkpoint inhibitors in metastatic renal cell carcinoma

Introduction Immune checkpoint inhibitors are one of the standard treatments for metastatic renal cell carcinoma. Among immune‐related adverse events, the sarcoidosis‐like reaction is frequently difficult to differentiate from cancer progression. Case presentation A 58‐year‐old man with renal cell c...

Full description

Bibliographic Details
Main Authors:	Akiyoshi Katagiri, Hiroyuki Yamazaki, Taro Ikeda
Format:	Article
Language:	English
Published:	Wiley 2022-01-01
Series:	IJU Case Reports
Subjects:	immune checkpoint inhibitor immune‐related adverse event renal cell carcinoma sarcoidosis‐like reaction
Online Access:	https://doi.org/10.1002/iju5.12372

Similar Items

Immune checkpoint inhibitor-associated sarcoidosis reaction
by: Parisa Keshtgar, et al.
Published: (2023-09-01)

Sarcoidosis-like reaction induced by immune checkpoint inhibitor in a patient with hepatocellular carcinoma: a case report
by: Alberto Torres-Zurita, et al.
Published: (2023-09-01)

Management of Immune-Related Adverse Events from Immune-Checkpoint Inhibitors in Advanced or Metastatic Renal Cell Carcinoma
by: Katharina Leucht, et al.
Published: (2022-09-01)

Suspected immune checkpoint inhibitor‐induced pulmonary sarcoid reaction in metastatic renal cell carcinoma
by: Victoria Purcell, et al.
Published: (2022-07-01)

Imaging Changes and Immune-Checkpoint Expression on T Cells in Bronchoalveolar Lavage Fluid from Patients with Pulmonary Sarcoidosis
by: Yasuaki Kotetsu, et al.
Published: (2021-09-01)

Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report
by: Tamotsu Sagawa, et al.
Published: (2023-07-01)

Hypereosinophilia is a predictive biomarker of immune checkpoint inhibitor-induced hypopituitarism in patients with renal cell carcinoma
by: Hodaka Yamada, et al.
Published: (2022-04-01)

Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature
by: Felipe Soto, et al.
Published: (2023-05-01)

Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis
by: Yao-Ning Feng, et al.
Published: (2023-06-01)

Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma
by: Mathew R. Birnbaum, BS, et al.
Published: (2017-05-01)

Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
by: Agnese Paderi, et al.
Published: (2021-02-01)

Blue-ink tattoo reaction associated with immune checkpoint inhibitor treatment of metastatic colorectal cancer, a case report
by: Nolan Holley, et al.
Published: (2024-03-01)

Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis
by: Hiroyuki Ando, et al.
Published: (2021-10-01)

A case of severe acute hemorrhagic duodenitis after administration of immune checkpoint inhibitor
by: Keita Saito, et al.
Published: (2022-04-01)

Immune Checkpoint Inhibitor–Associated Sarcoidosis Reaction in the Kidney: Case Report
by: Mariam Charkviani, et al.
Published: (2023-05-01)

IMMUNE CHECKPOINT INHIBITORS AND RHEUMATIC ADVERSE EVENTS
by: Ioana Cretu, et al.
Published: (2018-12-01)

Renal Sarcoidosis-like Reaction Induced by PD-1 Inhibitor Treatment in Non-Small Cell Lung Cancer: A Case Report and Literature Review
by: Sang-Don Park, et al.
Published: (2023-05-01)

Cardiovascular events after the initiation of immune checkpoint inhibitors
by: Yuta Suzuki, et al.
Published: (2023-05-01)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated adverse events in the digestive system
by: Yue Li, et al.
Published: (2020-04-01)

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events
by: Junling Zhuang, et al.
Published: (2020-03-01)

Clinical Diagnosis and Treatment Recommendations for Immune Checkpoint Inhibitor-related Hematological Adverse Events
by: Junling ZHUANG, et al.
Published: (2019-10-01)

Case Report: Successful immune checkpoint inhibitor-based rechallenge in a patient with advanced renal clear cell cancer
by: Shengxiu He, et al.
Published: (2023-10-01)

Recent Advance in Biomarkers for Predicting Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors
by: LI Ying, et al.
Published: (2021-04-01)

Research progress of immune checkpoint inhibitor related autoimmune hypophysitis
by: LI Jia-yi, XING Bing
Published: (2020-03-01)

Follow-up Care for Patients Receiving Immune Checkpoint Inhibitors
by: Liyan Zhang, et al.
Published: (2021-01-01)

Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis
by: Jingyang Su, et al.
Published: (2024-04-01)

Editorial: Immune checkpoint inhibitors in renal cell carcinoma
by: Scott S. Tykodi, et al.
Published: (2023-04-01)

Clinical Diagnosis and Treatment of Immune-related Adverse Events in Digestive System Related to Immune Checkpoint Inhibitors
by: Yue LI, et al.
Published: (2019-10-01)

Clinical Observation of Adverse Events of Immune Checkpoint Inhibitors in 20 Advanced Tumor Patients and Literature Reviews
by: WANG Xue, et al.
Published: (2020-06-01)

Rheumatic Immune-related Adverse Events and Treatment of Immune Checkpoint Inhibitors
by: ZHANG Xue, et al.
Published: (2020-11-01)

Clinical diagnosis and treatment of immune checkpoint inhibitors‐related endocrine dysfunction
by: Lian Duan, et al.
Published: (2020-04-01)

Immune Checkpoint Inhibitor-Induced Gastroduodenitis: Recurrence after Rechallenge with Pembrolizumab
by: Catarina O’Neill, et al.
Published: (2021-04-01)

Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?
by: Seon-Mi Lee, et al.
Published: (2023-01-01)

Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events
by: Busra Isik, et al.
Published: (2021-04-01)

Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review
by: Marion Allouchery, et al.
Published: (2022-02-01)

Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors
by: Tanja Mesti, et al.
Published: (2023-03-01)

Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms
by: Rishi Rikhi, et al.
Published: (2021-08-01)

Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database
by: Quentin Scanvion, et al.
Published: (2020-01-01)

Ocular adverse events associated with immune checkpoint inhibitors, a scoping review
by: A. Martens, et al.
Published: (2023-02-01)

Risk factors for cardiovascular adverse events from immune checkpoint inhibitors
by: Lingli Luo, et al.
Published: (2023-04-01)